Endocrine and Metabolic Prescription Medications for Dogs: Expert Guide to Diabetes, Thyroid and Hormone Treatments in the UK

Caninsulin VetPen is a veterinary-formulated porcine insulin zinc suspension offered in a pen format that simplifies dosing for dogs and reduces wastage compared with vial-only products. It is positioned as a cost-conscious, clinic-friendly option with dosing pens that improve owner compliance versus vial-based insulins like Prozinc, while providing a more veterinary-focused formulation than human products such as Lantus or Humulin N.

ProZinc is highlighted for its recombinant human insulin formulation combined with protamine to give a prolonged action and a lower theoretical immunogenicity compared with porcine insulins, making it a clinical preference for dogs that develop insulin antibodies or have erratic responses. Its technical advantages in terms of manufacturing and immunogenicity profile are balanced by a generally higher cost than porcine products like Vetsulin and Caninsulin, so ProZinc is often chosen for patients where therapeutic precision justifies the expense. In the 2025 UK guide ProZinc is recommended where long-term control and reduced antibody risk are priorities relative to cheaper oral options such as glipizide or endocrine modulators like Vetoryl.

Forthyron is a long-established levothyroxine formulation valued in veterinary practice for its consistent potency and easily titratable scored tablets, making dose adjustments straightforward for canine hypothyroidism. In this 2025 British guide it stands out for predictable bioavailability and cost-effectiveness compared with proprietary veterinary brands like Thyro‑Tabs Canine, Soloxine, Leventa and Thyrosyn, and it often undercuts brand-name levothyroxine tablets on price while delivering equivalent clinical results when monitored by a veterinarian. Its main advantage is broad availability and familiar therapeutic profile versus generics labelled simply as Levothyroxine Sodium Tablets, though careful monitoring remains essential due to the drug’s narrow therapeutic index.

Zycortal is a modern DOCP formulation licensed specifically for canine hypoadrenocorticism and designed for owner‑friendly administration with dosing schedules that can reduce clinic visits, offering a compelling balance of efficacy and convenience in the UK market. In this guide Zycortal is highlighted as a contemporary alternative to Percorten‑V, often providing more flexible administration options and competitive total cost of care thanks to reduced monitoring burden and subcutaneous dosing that some owners can perform at home. Technically it matches other DOCPs for mineralocorticoid effect but often scores higher on usability and adherence, which can improve long‑term outcomes.